The significance of these results cannot be overstated, as they have not only met but exceeded the predefined threshold for survival improvement set by the trial design. This milestone paves the way for launching a definitive Phase III randomized trial aimed at conclusively determining the therapeutic advantage offered by proton dose-escalation in newly diagnosed GBM patients. The results were formally presented at the prestigious American Society for Radiation Oncology (ASTRO) Annual Meeting held in San Francisco, further highlighting their importance to the wider medical research community.

Dr. Minesh P. Mehta, a leading figure at the Baptist Health Miami Cancer Institute and Florida International University’s Herbert Wertheim College of Medicine, and the principal investigator of the NRG-BN001 study, elaborated on the dual rationale behind this innovative trial approach. The team hypothesized that proton therapy’s inherent physical characteristics could permit safe dose escalation beyond the conventional standard of care by enhancing tumoricidal effects while simultaneously mitigating radiation exposure to circulating lymphocytes. Preservation of lymphocyte populations is critical, as these immune cells underlie the anti-tumor response essential for durable disease control.

The genesis of this trial can be traced back to multiple single-arm, non-randomized studies that had previously established the safety and potential efficacy of simultaneous integrated boost (SIB) radiation therapy delivering 75 Gy in conjunction with temozolomide chemotherapy. Despite the promise shown in these earlier studies, definitive evidence from randomized controlled trials was lacking, a gap that NRG-BN001 was specifically designed to address. Importantly, lymphopenia—frequently observed during photon-based radiation—has been implicated as a negative prognostic factor due to its dose-volume dependency and adverse influence on survival outcomes in GBM. Proton therapy’s ability to spare normal tissues from unnecessary radiation may thus serve a dual role, combining dose escalation benefits with immunologic preservation.

The trial enrolled 193 evaluable patients in the proton therapy arm, offering a robust sample size to assess clinical outcomes rigorously. Analysis revealed a hazard ratio (HR) for death of 0.81 favoring the proton arm, with a 70% confidence interval spanning 0.67 to 0.98, and a p-value of 0.11—significant given the prespecified Type I error rate of 0.15 for this signal-seeking design. When adjustments were made for biomarkers such as MGMT promoter methylation status and recursive partitioning analysis (RPA) classification, the survival advantage remained statistically significant, underscoring the robustness of the findings.

At the two-year survival mark, the absolute benefit of proton therapy compared to the control arm was 6.8%, translating to survival rates of 49.9% versus 43.1%, respectively. At three years, the proton arm maintained a notable 4.6% absolute advantage (30% vs. 25.4%). These figures are particularly compelling given the notoriously poor prognosis associated with GBM and the historically limited progress in improving long-term outcomes. Stratification analyses further demonstrated that both MGMT methylated tumors and patients with lower RPA classes derived superior OS benefits with proton therapy, with no significant interaction effects indicating that these factors did not modify the treatment response.

Safety profiles are a critical metric in evaluating the feasibility of dose intensification regimens. In this study, rates of high-grade toxicities were comparable between treatment groups. Notably, Grade 3 or higher lymphopenia occurred in 17.1% of patients receiving 75 Gy proton therapy versus 23.4% in the 60 Gy photon cohort, suggesting a meaningful reduction in immunosuppressive side effects. Moreover, severe neurologic toxicities (Grade 4 or above) were also lower in the proton group (1.8% vs. 5%), reinforcing the potential for improved tolerability alongside efficacy gains.

The biological basis underlying these clinical outcomes is rooted in the distinct physical and dosimetric properties of proton therapy. Protons exhibit a characteristic Bragg peak, which enables the delivery of high radiation doses confined to tumor volumes with minimal exit dose beyond the target. This precise energy deposition pattern reduces incidental irradiation of surrounding normal tissues, including critical immune organs and circulating lymphocytes, thereby improving the therapeutic ratio. Preservation of systemic immune competence during treatment may synergize with temozolomide-induced cytotoxicity and intrinsic anti-tumor immunity to enhance patient survival.

While the Phase II results are encouraging, the oncology field must await confirmation through larger, definitive Phase III trials designed to validate the survival benefit and confirm safety in a broader patient population. The NRG-BN001 proton cohort data provide a compelling rationale to justify such investment in further clinical investigation, potentially transforming standard care paradigms for GBM. Given the dismal outcomes historically linked to this aggressive glial malignancy, innovations that safely intensify local control while maintaining systemic immune function are particularly warranted.

This trial also highlights the evolving landscape of radiation oncology, where advanced technologies such as intensity-modulated proton therapy (IMPT) enable more precise treatment delivery. As these modalities become increasingly accessible, the integration of molecular and imaging biomarkers may further tailor therapy to individual patient tumor biology and immune status in a precision medicine framework.

Funding for the research underpinning these advancements was generously supported by multiple National Cancer Institute awards, including U10CA180868 (NRG Oncology Operations) and other supplemental grants, emphasizing the vital role of federally sponsored clinical trials infrastructure in driving cancer care innovation. The results were presented during the Plenary Session at ASTRO 2025, underscoring the scientific community’s recognition of the study’s potential impact.

In sum, the NRG-BN001 trial’s proton therapy arm has shed light on an auspicious strategy to improve outcomes in newly diagnosed GBM patients through dose intensification coupled with immune preservation. These findings mark a pivotal step forward, offering hope for enhanced survival in a patient population long constrained by limited therapeutic options. The oncology world eagerly anticipates subsequent Phase III confirmatory trials that could cement proton therapy’s role as a new cornerstone in GBM management.

Subject of Research: Proton versus photon radiation dose intensification in newly diagnosed glioblastoma (GBM) treatment

Article Title: Signal-Seeking Phase II Randomized Trial of Proton or IMRT Dose Intensification in GBM: NRG BN001

News Publication Date: September-October 2025

Web References:

• NRG Oncology Podcast: https://www.nrgoncology.org/Podcast
• ASTRO Annual Meeting 2025

References:
Mehta MP, Pugh SL, Mahajan A, Shih HA, Tsien CI, Chenevert TL, et al. Signal-Seeking Phase II Randomized Trial of Proton or IMRT Dose Intensification in GBM: NRG BN001. Presented at the ASTRO Annual Meeting, San Francisco, CA, 2025.

Keywords:
Glioblastoma, Proton Therapy, Radiation Dose Escalation, Temozolomide, Overall Survival, Lymphopenia, Intensity-Modulated Radiation Therapy (IMRT), Phase II Clinical Trial, NRG Oncology, Immunotherapy, Brain Cancer, Radiation Toxicity

Glioblastoma remains a formidable challenge due to its rapid growth, resistance to therapies, and inevitable recurrence, which collectively contribute to dismally low survival rates. Traditional prognostic factors such as age, performance status, and extent of surgical resection only partially explain patient variability. Thus, there is an acute demand for reliable, easily measurable biomarkers capable of refining prognosis and guiding post-treatment surveillance strategies.

The NLR, a simple blood-based inflammation marker derived by dividing the number of circulating neutrophils by lymphocytes, has garnered attention across multiple cancer types as a potential prognostic indicator. Elevated NLR values often reflect a systemic inflammatory state, which is implicated in tumor progression. However, its dynamic changes throughout treatment and their relevance in glioblastoma prognosis had not been fully elucidated—until now.

This pioneering study examined a cohort of 69 newly diagnosed GBM patients, all of whom underwent the standard aggressive treatment regimen known as the Stupp protocol, which combines surgical resection, radiotherapy, and chemotherapy with temozolomide. Researchers meticulously measured NLR at carefully selected time points: preoperative, post-concurrent chemoradiotherapy (post-CCRT), and post-Stupp protocol completion, focusing on how shifts in NLR—quantified as dynamic NLR (dNLR)—related to overall survival (OS) and progression-free survival (PFS).

Analysis revealed striking associations between the post-Stupp NLR and patient outcomes. Specifically, patients exhibiting a post-Stupp NLR of 5 or higher, or a dynamic NLR increase—defined as dNLR greater than or equal to 1.3—faced significantly poorer overall survival. These findings persisted even when adjusted for crucial clinical confounders such as age at diagnosis, preoperative Karnofsky Performance Score (KPS), and extent of tumor resection, underscoring the NLR’s independent prognostic value.

Notably, multivariate Cox regression models unveiled that older age (≥70 years), a lower preoperative functional status (KPS ≥60), and the aforementioned thresholds of post-Stupp NLR and dNLR were all significantly linked to higher mortality risks. The dynamic nature of NLR, capturing changes induced by treatment and tumor-host interactions, may offer a more nuanced prognostic signal than static pre-treatment values alone.

Beyond overall survival, the study also highlighted the role of NLR dynamics in progression-free survival. Post-Stupp dNLR elevations correlated with shorter intervals before tumor recurrence, suggesting that escalating systemic inflammation or immunosuppression might prelude radiographic or clinical relapse of GBM. This opens the intriguing possibility that serial monitoring of NLR could serve as a minimally invasive surveillance biomarker, potentially heralding recurrence prior to conventional imaging detection.

The biological rationale behind NLR’s prognostic power lies in the intricate tumor-immune crosstalk characterizing glioblastoma. Neutrophils contribute to tumor growth and invasion through secretion of proteases, cytokines, and pro-angiogenic factors, while lymphocytes, particularly cytotoxic T cells, mediate antitumor immunity. Thus, a high NLR denotes a shift towards a pro-tumoral, immunosuppressive environment—a finding corroborated across diverse malignancies.

Moreover, the dynamic changes in NLR reflecting treatment response or failure emphasize the evolving nature of the tumor microenvironment. As chemoradiotherapy modulates immune profiles, patients whose NLR increases might harbor residual aggressive disease or developing resistance, thereby experiencing accelerated progression.

These insights align with a growing paradigm recognizing systemic inflammation as a modifiable factor in cancer management and highlight the importance of integrating immunological biomarkers into personalized treatment planning. If validated in larger cohorts, NLR dynamics could enrich clinical decision-making, guiding intensified therapies or enrollment into immunomodulatory clinical trials for those identified at high risk.

The study is not without limitations. Its relatively modest sample size and single-center design necessitate external validation before widespread clinical adoption. Additionally, the optimal timing and frequency of NLR measurements to maximize prognostic accuracy remain to be defined. The influence of confounding factors such as infections or corticosteroid use, which can affect white blood cell counts, also warrants closer scrutiny.

Nonetheless, this research exemplifies the power of accessible, cost-effective biomarkers to transform neuro-oncology practice. Blood tests like NLR are routinely performed, and leveraging their dynamics could provide clinicians with real-time insights into disease trajectory, complementing imaging and clinical evaluation.

In conclusion, the identification of post-Stupp NLR and dynamic NLR as robust prognostic markers in glioblastoma marks an exciting advancement in the quest to personalize care for patients afflicted with this devastating malignancy. These findings set the stage for future prospective studies and underscore the potential of immunological biomarkers in the ongoing endeavor to surveil glioblastoma recurrence and improve patient survival.

As the scientific community continues to unravel the immunobiology of glioblastoma, integrating dynamic biomarkers such as NLR into routine clinical workflows may soon enhance the precision of prognosis and treatment adjustments. Such strides bring hope that the grim outlook of glioblastoma can be gradually mitigated through informed, data-driven clinical interventions.

Subject of Research: Glioblastoma prognosis and recurrence monitoring using neutrophil-to-lymphocyte ratio dynamics.

Article Title: Neutrophil-to-lymphocyte ratio dynamics: prognostic value and potential for surveilling glioblastoma recurrence.

Article References:
Chung, MW., Tzeng, CC., Huang, YC. et al. Neutrophil-to-lymphocyte ratio dynamics: prognostic value and potential for surveilling glioblastoma recurrence. BMC Cancer 25, 709 (2025). https://doi.org/10.1186/s12885-025-14118-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14118-8